Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Bastian, Arangassery R ^a,b   Contarino, Mark ^a   Bailey, Lauren D ^a   Aneja, Rachna ^a   Moreira, Diogo R M ^a,c   Freedman, Kevin ^d   McFadden, Karyn ^e   Duffy, Caitlin ^a   Emileh, Ali ^f   Leslie, George ^g   Jacobson, Jeffrey M ^a   Hoxie, James A ^g   Chaiken, Irwin ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b DREXEL UNIVERSITY   (United States)

^c FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^d Drexel University   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f DARTMOUTH COLLEGE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ARGINYLISOLEUCYLASPARAGINYLASPARAGINYLISOLEUCYLFERROCENYLTRIAZOLE PROPYLTRYPTOPHYLSERYLGLUTAMYLALANYLMETHIONYLMETHIONYL BETA ALANYLGLUTAMINYL BETA ACETYLAMIDE; ARGINYLISOLEUCYLASPARAGINYLASPARAGINYLISOLEUCYLFERROCENYLTRIAZOLE PROPYLTRYPTOPHYLSERYLGLUTAMYLALANYLMETHIONYLMETHIONYLAMIDE; ENFUVIRTIDE; GAG PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; GLYCOPROTEIN GP 41 ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN KR13B; PROTEIN KR13S; TRIAZOLETHIOL; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CLADISTICS; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MEMBRANE FUSION; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STRUCTURE; VIRION; VIRUS BREAKDOWN; VIRUS CAPSID; VIRUS ENVELOPE; VIRUS INACTIVATION; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS SHEDDING; VIRUS TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE;

ANTIVIRAL AGENTS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; PEPTIDES; PROTEIN CONFORMATION; SULFHYDRYL COMPOUNDS; TRIAZOLES; VIRION; VIRUS INACTIVATION;

EID: 84889973515     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-153     Document Type: Article

References (60)

1. Potthoff AV, Brockmeyer NH. Current therapy of HIV. J Dtsch Dermatol Ges 2010, 8(1):45-56. quiz 57-48.
2. Dau B, Holodniy M. Novel targets for antiretroviral therapy: clinical progress to date. Drugs 2009, 69(1):31-50.
3. Hendrix CW. The clinical pharmacology of antiretrovirals for HIV prevention. Curr Opin HIV AIDS 2012, 7(6):498-504.
4. Hertje M, Zhou M, Dietrich U. Inhibition of HIV-1 entry: multiple keys to close the door. Chem Med Chem 2010, 5(11):1825-1835.
5. Qiu S, Yi H, Hu J, Cao Z, Wu Y, Li W. The binding mode of fusion inhibitor T20 onto HIV-1 gp41 and relevant T20-resistant mechanisms explored by computational study. Curr HIV Res 2012, 10(2):182-194.
6. Kromdijk W, Huitema AD, Mulder JW. Treatment of HIV infection with the CCR5 antagonist maraviroc. Expert Opin Pharmacother 2010, 11(7):1215-1223.
7. Perry CM. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection. Drugs 2010, 70(9):1189-1213.
8. Haqqani AA, Tilton JC. Entry inhibitors and their use in the treatment of HIV-1 infection. Antiviral Res 2013, 98(2):158-170.
9. Henrich TJ, Kuritzkes DR. HIV-1 entry inhibitors: recent development and clinical use. Curr Opin Virol 2013, 3(1):51-57.
10. Champagne K, Shishido A, Root MJ. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil. J Biol Chem 2009, 284(6):3619-3627.
11. Wallace BJ, Tan KB, Pett SL, Cooper DA, Kossard S, Whitfeld MJ. Enfuvirtide injection site reactions: a clinical and histopathological appraisal. Australas J Dermatol 2011, 52(1):19-26.
12. Emmelkamp JM, Rockstroh JK. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions-review of the literature. Eur J Med Res 2007, 12(9):409-417.
13. Nettles RE, Schurmann D, Zhu L, Stonier M, Huang SP, Chang I, Chien C, Krystal M, Wind-Rotolo M, Ray N, et al. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J Infect Dis 2012, 206(7):1002-1011.
14. Debnath AK. Rational design of HIV-1 entry inhibitors. Methods Mol Biol 2013, 993:185-204.
15. Hicks C, Clay P, Redfield R, Lalezari J, Liporace R, Schneider S, Sension M, McRae M, Laurent JP. Safety, tolerability, and efficacy of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV type 1-infected subjects. AIDS Res Hum Retroviruses 2013, 29(2):250-255.
16. Neffe AT, Bilang M, Gruneberg I, Meyer B. Rational optimization of the binding affinity of CD4 targeting peptidomimetics with potential anti HIV activity. J Med Chem 2007, 50(15):3482-3488.
17. Madani N, Schon A, Princiotto AM, Lalonde JM, Courter JR, Soeta T, Ng D, Wang L, Brower ET, Xiang SH, et al. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 2008, 16(11):1689-1701.
18. Lalonde JM, Le-Khac M, Jones DM, Courter JR, Park J, Schon A, Princiotto AM, Wu X, Mascola JR, Freire E, et al. Structure-based design and synthesis of an HIV-1 entry inhibitor exploiting X-Ray and thermodynamic characterization. ACS Med Chem Lett 2013, 4(3):338-343.
19. Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP, Lewis ST. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 2009, 53(2):450-457.
20. Jacobson JM, Lalezari JP, Thompson MA, Fichtenbaum CJ, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. Antimicrob Agents Chemother 2010, 54(10):4137-4142.
21. Olson WC, Jacobson JM. CCR5 monoclonal antibodies for HIV-1 therapy. Curr Opin HIV AIDS 2009, 4(2):104-111.
22. Matz J, Kessler P, Bouchet J, Combes O, Ramos OH, Barin F, Baty D, Martin L, Benichou S, Chames P. Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. J Virol 2013, 87(2):1137-1149.
23. Kwong PD, Mascola JR, Nabel GJ. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol 2013, 13(9):693-701.
24. McCoy LE, Weiss RA. Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med 2013, 210(2):209-223.
25. Flexner C, Saag M. The antiretroviral drug pipeline: prospects and implications for future treatment research. Curr Opin HIV AIDS 2013, 8(6):572-578.
26. Sharma AK, George V, Valiathan R, Pilakka-Kanthikeel S, Pallikkuth S. Inhibitors of HIV-1 entry and integration: recent developments and impact on treatment. Recent Pat Inflamm Allergy Drug Discov 2013, 7(2):151-161.
27. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC. Antibodies in HIV-1 vaccine development and therapy. Science 2013, 341(6151):1199-1204.
28. Umashankara M, McFadden K, Zentner I, Schon A, Rajagopal S, Tuzer F, Kuriakose SA, Contarino M, Lalonde J, Freire E, et al. The active core in a triazole peptide dual-site antagonist of HIV-1 gp120. ChemMedChem 2010, 5(11):1871-1879.
29. McFadden K, Fletcher P, Rossi F, Kantharaju K, Umashankara M, Pirrone V, Rajagopal S, Gopi H, Krebs FC, Martin-Garcia J, et al. Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors. Antimicrob Agents Chemother 2012, 56(2):1073-1080.
30. Gopi H, Umashankara M, Pirrone V, LaLonde J, Madani N, Tuzer F, Baxter S, Zentner I, Cocklin S, Jawanda N, et al. Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1. J Med Chem 2008, 51(9):2638-2647.
31. Gopi HN, Tirupula KC, Baxter S, Ajith S, Chaiken IM. Click chemistry on azidoproline: high-affinity dual antagonist for HIV-1 envelope glycoprotein gp120. ChemMedChem 2006, 1(1):54-57.
32. Cocklin S, Gopi H, Querido B, Nimmagadda M, Kuriakose S, Cicala C, Ajith S, Baxter S, Arthos J, Martin-Garcia J, et al. Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor. J Virol 2007, 81(7):3645-3648.
33. Tuzer F, Madani N, Kamanna K, Zentner I, LaLonde J, Holmes A, Upton E, Rajagopal S, McFadden K, Contarino M, et al. HIV-1 Env gp120 structural determinants for peptide triazole dual receptor site antagonism. Proteins 2013, 81(2):271-290.
34. Emileh A, Tuzer F, Yeh H, Umashankara M, Moreira DR, Lalonde JM, Bewley CA, Abrams CF, Chaiken IM. A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption. Biochemistry 2013, 52(13):2245-2261.
35. Kamanna K, Aneja R, Duffy C, Kubinski P, Rodrigo Moreira D, Bailey LD, McFadden K, Schon A, Holmes A, Tuzer F, et al. Non-natural peptide triazole antagonists of HIV-1 envelope gp120. ChemMedChem 2013, 8(2):322-328.
36. Cantin R, Diou J, Belanger D, Tremblay AM, Gilbert C. Discrimination between exosomes and HIV-1: purification of both vesicles from cell-free supernatants. Immunol Methods 2008, 338(1-2):21-30.
37. Gopi H, Cocklin S, Pirrone V, McFadden K, Tuzer F, Zentner I, Ajith S, Baxter S, Jawanda N, Krebs FC, et al. Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120. J Mol Recognit 2009, 22(2):169-174.
38. Zhang W, Godillot AP, Wyatt R, Sodroski J, Chaiken I. Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4. Biochemistry 2001, 40(6):1662-1670.
39. Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, Cohen FS. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 2000, 151(2):413-423.
40. Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 2004, 78(9):4628-4637.
41. Bastian AR, Kantharaju K, McFadden K, Duffy C, Rajagopal S, Contarino MR, Papazoglou E, Chaiken I. Cell-free HIV-1 virucidal action by modified peptide triazole inhibitors of Env gp120. ChemMedChem 2011, 6(8):1335-1339. 1318.
42. Matthias LJ, Yam PT, Jiang XM, Vandegraaff N, Li P, Poumbourios P, Donoghue N, Hogg PJ. Disulfide exchange in domain 2 of CD4 is required for entry of HIV-1. Nat Immunol 2002, 3(8):727-732.
43. Ryser HJ, Levy EM, Mandel R, DiSciullo GJ. Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction. Proc Natl Acad Sci USA 1994, 91(10):4559-4563.
44. Hogg PJ. Disulfide bonds as switches for protein function. Trends Biochem Sci 2003, 28(4):210-214.
45. Shen X, Parks RJ, Montefiori DC, Kirchherr JL, Keele BF, Decker JM, Blattner WA, Gao F, Weinhold KJ, Hicks CB, et al. In vivo gp41 antibodies targeting the 2 F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol 2009, 83(8):3617-3625.
46. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993, 9(11):1051-1053.
47. Covens K, Megens S, Dekeersmaeker N, Kabeya K, Balzarini J, De Wit S, Vandamme AM, Van Laethem K. The rare HIV-1 gp41 mutations 43 T and 50 V elevate enfuvirtide resistance levels of common enfuvirtide resistance mutations that did not impact susceptibility to sifuvirtide. Antiviral Res 2010, 86(3):253-260.
48. Wood MP, Cole AL, Ruchala P, Waring AJ, Rohan LC, Marx P, Tarwater PM, Gupta P, Cole AM. A compensatory mutation provides resistance to disparate HIV fusion inhibitor peptides and enhances membrane fusion. PloS One 2013, 8(2):e55478.
49. Sullivan N, Sun Y, Binley J, Lee J, Barbas CF, Parren PW, Burton DR, Sodroski J. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J Virol 1998, 72(8):6332-6338.
50. Schon A, Madani N, Klein JC, Hubicki A, Ng D, Yang X, Smith AB, Sodroski J, Freire E. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry 2006, 45(36):10973-10980.
51. Lackman-Smith C, Osterling C, Luckenbaugh K, Mankowski M, Snyder B, Lewis G, Paull J, Profy A, Ptak RG, Buckheit RW, et al. Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob Agents Chemother 2008, 52(5):1768-1781.
52. Bobardt MD, Cheng G, de Witte L, Selvarajah S, Chatterji U, Sanders-Beer BE, Geijtenbeek TB, Chisari FV, Gallay PA. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proc Natl Acad Sci USA 2008, 105(14):5525-5530.
53. Ruprecht CR, Krarup A, Reynell L, Mann AM, Brandenberg OF, Berlinger L, Abela IA, Regoes RR, Gunthard HF, Rusert P, et al. MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J Exp Med 2011, 208(3):439-454.
54. Thali M, Furman C, Helseth E, Repke H, Sodroski J. Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events. J Virol 1992, 66(9):5516-5524.
55. Moore JP, McKeating JA, Weiss RA, Sattentau QJ. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 1990, 250(4984):1139-1142.
56. Morton TA, Bennett DB, Appelbaum ER, Cusimano DM, Johanson KO, Matico RE, Young PR, Doyle M, Chaiken IM. Analysis of the interaction between human interleukin-5 and the soluble domain of its receptor using a surface plasmon resonance biosensor. J Mol Recognit 1994, 7(1):47-55.
57. He J, Landau NR. Use of a novel human immunodeficiency virus type 1 reporter virus expressing human placental alkaline phosphatase to detect an alternative viral receptor. J Virol 1995, 69(7):4587-4592.
58. Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol 2005, 12. 12.11.1-12.11.17. Doi: No. 10.1002/0471142735.im1211s64.
59. Thavarajah R, Mudimbaimannar VK, Elizabeth J, Rao UK, Ranganathan K. Chemical and physical basics of routine formaldehyde fixation. J Oral Maxillofac Pathol 2012, 16(3):400-405.
60. Takashima K, Miyake H, Furuta RA, Fujisawa JI, Iizawa Y, Kanzaki N, Shiraishi M, Okonogi K, Baba M. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication. Antimicrob Agents Chemother 2001, 45(12):3538-3543.